Arbutus Biopharma (NASDAQ:ABUS) Raised to Hold at StockNews.com

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report issued on Wednesday.

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. Chardan Capital reaffirmed a "buy" rating and issued a $5.00 price objective (up from $4.50) on shares of Arbutus Biopharma in a research report on Wednesday, November 20th. Finally, JMP Securities increased their price target on shares of Arbutus Biopharma to $5.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $5.50.

Arbutus Biopharma Stock Down 1.8 %

Shares of Arbutus Biopharma stock traded down $0.06 during midday trading on Wednesday, hitting $3.31. The company had a trading volume of 1,191,920 shares, compared to its average volume of 1,019,151. The stock has a market cap of $627.22 million, a price-to-earnings ratio of -7.70 and a beta of 1.93. The company has a fifty day simple moving average of $3.34 and a 200 day simple moving average of $3.64. Arbutus Biopharma has a 12-month low of $2.30 and a 12-month high of $4.73.

Remove Ads

Hedge Funds Weigh In On Arbutus Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Whitefort Capital Management LP grew its stake in shares of Arbutus Biopharma by 2.9% during the 4th quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company's stock worth $43,301,000 after purchasing an additional 373,949 shares during the period. Vanguard Group Inc. grew its stake in shares of Arbutus Biopharma by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company's stock worth $29,367,000 after purchasing an additional 62,282 shares during the period. Two Seas Capital LP grew its stake in shares of Arbutus Biopharma by 4.2% during the 4th quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company's stock worth $28,583,000 after purchasing an additional 353,568 shares during the period. State Street Corp grew its stake in shares of Arbutus Biopharma by 50.2% during the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company's stock worth $16,967,000 after purchasing an additional 1,472,652 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Arbutus Biopharma by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 3,482,136 shares of the biopharmaceutical company's stock worth $11,390,000 after purchasing an additional 33,536 shares during the period. Institutional investors and hedge funds own 43.79% of the company's stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.